Clinical Trial Detail

NCT ID NCT01433991
Title E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Eisai Inc.
Indications

Advanced Solid Tumor

Therapies

Golvatinib

Lenvatinib

Age Groups: adult child senior

No variant requirements are available.